Vaccination Recommendations Before Starting Kesimpta (Ofatumumab)
You should receive pneumococcal vaccines (PCV20 or PCV15 followed by PPSV23), COVID-19 vaccine, recombinant zoster vaccine (Shingrix), hepatitis B vaccine series, and meningococcal vaccines (MenACWY and MenB) before starting Kesimpta, with all vaccines administered at least 4 weeks before your first dose for live vaccines and at least 2 weeks before for inactivated vaccines.
Critical Timing: Vaccinate NOW Before Starting Therapy
The FDA label for Kesimpta explicitly states that all immunizations should be administered "at least 4 weeks prior to initiation of KESIMPTA for live or live-attenuated vaccines, and whenever possible, at least 2 weeks prior to initiation of KESIMPTA for inactivated vaccines" 1. This timing is crucial because ofatumumab is an anti-CD20 monoclonal antibody that depletes B-cells, which will significantly impair your ability to mount effective antibody responses to vaccines once treatment begins 2.
Specific Vaccines You Need
High Priority (Get These Immediately):
Pneumococcal Vaccines:
- Either PCV20 (single dose) OR PCV15 followed by PPSV23 8 weeks later
- You are at increased risk for invasive pneumococcal disease on B-cell depleting therapy
COVID-19 Vaccine:
- Complete the updated COVID-19 vaccine series
- Anti-CD20 therapies like ofatumumab significantly reduce antibody responses to COVID-19 vaccines 2
- Timing: ideally 4-6 weeks before starting ofatumumab 2
Recombinant Zoster Vaccine (Shingrix):
- Two doses, 2-6 months apart
- This is a recombinant (non-live) vaccine, safe for immunocompromised patients 3
- Start the series now; you can receive the first dose at least 2 weeks before starting Kesimpta
Hepatitis B Vaccine:
- Three-dose series (0,1,6 months) with post-vaccination serology
- Check HBsAg, anti-HBs, and anti-HBc before starting Kesimpta (required screening per FDA label) 1
- If you're HBV-naïve, start the series immediately 4
Meningococcal Vaccines:
- MenACWY: 2 doses, 8 weeks apart (for patients on complement-inhibiting or B-cell depleting therapies) 5
- MenB: 2 doses (Bexsero) 1 month apart OR 3 doses (Trumenba) at 0,1-2, and 6 months 5
- These are critical because B-cell depletion increases your risk of invasive meningococcal disease
Standard Vaccines (Ensure Up-to-Date):
Annual Influenza Vaccine:
- Get the current season's vaccine
- High-dose or adjuvanted formulations may provide better immune response 6, 7
- Continue annually while on ofatumumab, though responses will be attenuated 6
Tdap Booster:
- If not received in the last 10 years 4
How Kesimpta Affects Your Immune System
Ofatumumab causes rapid and sustained near-complete B-cell depletion starting within days of the first injection 8. Here's what this means:
- B-cell depletion begins immediately and is maintained with monthly 20mg doses 8
- Antibody responses to vaccines are significantly impaired during treatment 2, 1
- IgM levels decrease significantly during treatment, though IgG levels remain relatively stable over 4 years 9, 10
- Cellular (T-cell) immunity is preserved, providing some protection even when antibody responses are blunted 11
- B-cell recovery occurs within months after stopping therapy, unlike some other anti-CD20 therapies 12
The key difference from other anti-CD20 therapies: Ofatumumab's subcutaneous administration and selective targeting of lymphatic B-cells preserves CD20-expressing B-cell progenitors in bone marrow, maintaining some capacity for plasma cell differentiation 12. However, this does NOT mean vaccines will work normally during treatment.
Critical Pitfalls to Avoid
Do NOT delay vaccination until after starting Kesimpta - your neurologist's office saying they have "no recommendations" is inadequate. The FDA label explicitly requires vaccination beforehand 1.
Do NOT receive live vaccines (MMR, varicella, live zoster, yellow fever, live intranasal flu) once you start Kesimpta or until B-cells recover after stopping 1. This is why Shingrix (recombinant) is recommended instead of Zostavax (live).
Do NOT assume you can "catch up" on vaccines later - vaccine efficacy is dramatically reduced during B-cell depletion 2.
Do NOT skip hepatitis B screening - this is mandatory before starting Kesimpta per FDA label 1. Active HBV is a contraindication, and carriers require specialist consultation.
Practical Timeline for Your Situation
Week -4 to -2 (NOW):
- Get hepatitis B screening (HBsAg, anti-HBs, anti-HBc)
- Start hepatitis B vaccine series (dose 1)
- Get COVID-19 vaccine (if not recently vaccinated)
- Get PCV20 or PCV15
- Get MenACWY (dose 1)
- Get MenB (dose 1)
- Get Shingrix (dose 1)
- Get current flu vaccine
- Confirm Tdap status
Week -2 to 0:
- Continue waiting period for vaccine immune response development
Week 0:
- Start Kesimpta (first dose under healthcare supervision per FDA label) 1
After Starting Kesimpta:
- Complete multi-dose vaccine series that were started (hepatitis B doses 2 and 3, MenACWY dose 2, MenB dose 2, Shingrix dose 2) - though responses will be attenuated, some protection is better than none
- Get annual flu vaccines (reduced efficacy expected but still recommended) 6, 7
What the Evidence Shows
The most recent IDSA 2025 guidelines for immunocompromised patients recommend that those receiving B-cell depleting therapies should ideally receive vaccines "≥2 weeks before starting treatment and ≥3-6 months after last infusion" 7. For ofatumumab specifically, the 2022 guideline on COVID-19 vaccination in MS patients states vaccines should be given "4-6 weeks before starting treatment or 4-6 months after ending treatment" for anti-CD20 therapies 2.
Real-world data on ofatumumab shows excellent disease control (91% NEDA-3 rates) with a favorable safety profile, but infections remain a concern, particularly in those with low immunoglobulin levels 10, 13. Vaccination before therapy is your best protection against preventable infections.
Bottom line: Contact your PCP today to start this vaccination series immediately. Do not start Kesimpta until you've received at least the first doses of these vaccines with appropriate waiting periods.